Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
OwnerWayne Godfrey, Edgar Englemaninventors
Life of this patent
Estimating the term…
Abstract
The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4+ T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified extracellular domains of ligands. The invention also provides humanized and human antibodies to the ligand. The invention further provides methods of using the ligand and the antibodies in treatment of diseases and conditions of the immune system. The invention also provides methods of monitoring activated CD4+ T-cells using the ligands or fragments thereof.
Claims21
A purified ACT-4-L ligand polypeptide having a segment between 5 and 160 contiguous amino acids from an amino acid sequence shown in FIG. 10.
A purified extracellular domain of an ACT-4-L ligand comprising at least five contiguous amino acids from the full-length ACT-4-L-h-1 extracellular domain.
21-50. (canceled)
Dependencies are inferred from the claim text.